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Deriving the proportion of variance in 25(OH)D tagged by SNP instruments 
The proportion of variance on the exposure (X) explained by SNP instruments, denoted as 𝑟𝑡𝑜𝑡𝑎𝑙
2  
can be derived using: 
𝑟𝑡𝑜𝑡𝑎𝑙
2 =




for m independent 25(OH)D SNP instruments where 𝑝𝑖 refer to the effect allele frequency of 
𝑆𝑁𝑃𝑖 and 𝛽𝑖 refer to magnitude of association between 𝑆𝑁𝑃𝑖 with X.  
 
Power calculations for Mendelian randomization analyses 
We estimated the statistical power to detect an association between a one SD change in 
genetically predicted 25(OH)D and cancer risk at various pragmatic cut-offs (OR>1.1, OR>1.2 
and OR>1.4) using the mRnd (http://cnsgenomics.com/shiny/mRnd/) online MR power 
calculator 1. We set the proportion of phenotypic variance (25(OH)D) explained by SNPs to be 
4.5%. The estimated power for each of the cancer MR analyses were shown in Supplementary 
Table 2. 
 
Estimating the between-sex genetic correlation for serum 25(OH)D levels  
Sex-specific genetic markers can potentially yield more accurate causal estimates for MR if the 
SNP-exposure association differs between sexes. We first evaluated the genetic correlation on 
25(OH)D between white British men and women in the UKB through linkage disequilibrium (LD) 
score regression 2using the GWAS summary statistics on rank-transformed 25(OH)D 
concentration performed separately for men and women. The data cleaning and curation of both 
of these GWAS datasets were similar to the approach adopted in the main text other than 
individuals of the opposing sex being excluded (rather than fitting sex as a covariate, all women 
were excluded from the male-specific GWAS, vice versa). The LD-score derived genetic 
correlation is 0.9599 (se: 0.0287) indicating substantially high genetic overlap between 25(OH)D 
in men and women providing poor rationale for the use of sex-specific instrument. Hence, we 
proceeded our MR analyses using only the 25(OH)D GWAS performed on both sex combined 
(genetic sex only fitted as a covariate in the GWAS model) in the UKB to maximise power for 
instrument detection.   
 
Description of the QSkin cohort 
The QSkin cohort 3 is a large Australian-based prospective study on skin cancers. The cohort 
consists of 43 794 young to middle aged (40-69) adults, the majority being of white European 
ancestry.  The primary aim of the study is to identify and evaluate both environmental and 
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genetic risk factors associated with skin cancer. Data on each participant’s phenotype, lifestyle, 
behaviour and exposures to environmental risk factors were obtained through self-report, in 
2011. Keratinocyte cancers (KC) are not routinely registered in the Australian cancer registries, 
hence health administration data obtained from the Australian Medicare database were used to 
identify individuals that underwent treatments for KCs for the period upon date of consent 
through to June 30, 2014. Exact diagnosis of KCs (BCC and SCC) were established through 
further linkage with medical (pathology) records. The complete description of the cohort profile 
for QSkin can be found elsewhere 3.  
 
Description of the 23andMe cohort 
The 23andMe company 4 is a personalised genomics USA-based corporation, with its 
headquarters situated in Mountain View, California, USA. The company has a huge customer 
base that consented for participation in research. As per GWAS analyses in Liyanage et al. 5, 
23andMe GWAS summary data on SCC and BCC 6,7 were derived from 23andMe participants 
who answered the self-reported questionnaire on whether they had a history of SCC/BCC 
diagnosis. The accuracy of the self-reported SCC and BCC status were verified clinically 
through a separate clinical study where Chahal et al. 7 showed good concordance between the 
self-report data and medical records. Genotyping for the 23andMe participants was conducted 
using several different customised  arrays, which included custom variants and variants tagged 
from the Illumina HumanHap550+ BeadChip, and Illumina OmniExpress+ BeadChip arrays 6. 
 
Source of GWAS summary statistics for each cancer 
The GWAS summary statistics for breast cancer risk reported in Michailidou et al. 5,8 was 
obtained from the official BCAC online repository, available here: 
http://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/. The GWAS summary statistics for the 
prostate cancer risk reported in Schumacher et al. 9 was obtained from the official BCAC online 
repository, available here: http://practical.icr.ac.uk/blog/?page_id=8164. The GWAS data 
accompanying the work by Phelan et al. 10 is publicly available and can be obtained through 
written request to the OCAC program committee (http://ocac.ccge.medschl.cam.ac.uk/). The 
ILCCO GWAS for lung cancer 11, as well as the genetic summary data on neuroblastoma and 
pancreatic cancer (PanScan) were already deposited in the MR-Base database and we 
analysed these data directly through the MR-web based interface (http://app.mrbase.org/). 
Genetic summary data for melanoma (GenoMEL) 12 and esophageal cancers (BEACON) 13 
were provided through formal application for use of the data through the respective program 
committee for each consortium. Data for the SCC and BCC GWAS meta-analysis can be 
obtained from written request to Dr. Stuart MacGregor (email: 





Literature search for previous published MR findings for 25(OH)D and individual 
cancers 
We performed a literature search on the PUBMED/PUBMED Central database published 
articles detailing MR findings between 25(OH)D concentration and cancer risks for cancers 
evaluated in our present analysis. The following keywords were used in combinations: 
“Mendelian randomization”, “Mendelian randomisation”, “Cancer risk”, “Cancers”, “Melanoma”, 
“Keratinoctye cancers”, “Vitamin D”, “25(OH)D”, “genetically predicted vitamin D”, “causal 
inference”, “instrumental variable”. Publications for each individual type of cancer were then 
filtered for the following criteria: (i) total sample size exceeds 2000. (ii) Reported effect 
estimates for quantifiable changes in 25(OH)D concentration (i.e. nmol/L, log(nmol/L) or SD 
units). (iii) Analyses based on European participants. For individuals with multiple published MR 
findings, we prioritise to select only the study with the largest sample size. 
 
 
Description of alternative MR causal effect estimators applied in the MR analysis 
Weighted median estimator 
The weighted median MR estimator 14 enables consistent estimation of the MR causal effect 
even when close to 50% of instruments are invalid instruments. The penalised weighted median 
model is a slight modification of the weighted median estimator by down-weighting SNPs that 
are highly heterogeneous ratio estimates. 
 
Weighted mode estimator 
In contrast to the median-based estimators, the mode based estimators 15 does not require 
more than 50% of the instruments being valid. Instead, the mode based estimators yield 
consistent estimates even when majority instruments are invalid instruments by relying on 
plurality such that ratio estimands from the largest subset of variants with similar effect sizes 
(largest group) constitute the true estimate. The weighted mode estimator assumes that the 
most frequent ratio estimand across all instrument is zero (also known as the Zero Modal 
Pleiotropy Assumption, ZEMPA).  
 
MR-Egger 
MR-Egger regression help detect the presence of directional pleiotropy in IVW MR findings 
(captured by the MR-Egger intercept) and provide less biased estimates of the causal effect. 
The method relies on the InSIDE assumption 16 being valid. 
 
MR-PRESSO 
MR-PRESSO 17 is a leave-one-out based approach that evaluates the extent of horizontal 
pleiotropy bias and heterogeneity in MR causal estimates.The approach can be summarised in 
three steps. First, MR-PRESSO performs a global test to evaluate whether the total residual 
sums of squares (RSS) (which was computed by leaving one SNP out in turn) is consistent with 
those expected by chance. The model then performs an outlier test by utilizing the RSS of 
individual SNPs to identify outliers. The final stage incorporates a distortion test to evaluate 
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which identified outlier meaningfully changed the MR causal estimates. We used the following 
default setting for each trait-pair analysed: number of iterations=4000, distortion_test=TRUE, 
outlier_test=TRUE, alpha=0.05. The MR-PRESSO software can be readily downloaded from 
https://github.com/rondolab/MR-PRESSO. 
 
IVW Radial regressions 
The IVW Radial regression 18 is a modified IVW regression of the form of   
beta-wald = Beta_radial*(sqrt(weight)) + error  
Where beta-wald refers to the wald-type ratio estimator, and the weight represents the original 
user defined inverse-variance weights. The IVW Radial allows for a more accurate identification 
of outliers as compared to the traditional IVW regression. The Radial MR R package is readily 
available for download from https://github.com/WSpiller/RadialMR.  
 
Preparation of GWAS on sun-exposure and pigmentation phenotypes for 
multivariable MR analysis 
We used self-reported data from the UK Biobank to perform a GWAS on hair colour, skin colour, 
sunburns to evaluate these traits alongside with 25(OH)D in a formal multivariable MR 
framework. For individuals reporting information across multiple instances (through multiple 
visits), only self-reported data from the first instance (instance 0) were used. A brief description 
of the individual GWAS for each trait examined and performed only among UKB participants of 
white British ancestry is provided below.  
 
Episodes of childhood sunburn. Data for hair colour in the UK Biobank was collated from the 
UKB field-ID: 1737 from 498 430 participants where the question “Before the age of 15, how 
many times did you suffer sunburn that was painful for at least 2 days or caused blistering?” 
was asked. The mean of the reported episodes of childhood sunburn was 1.627 (with sd of 5). 
Individuals that report more than 100 episodes were excluded. The GWAS for the facial aging 
trait was performed as a quantitative phenotype through a linear mixed model implemented in 
BOLT-LMM 20. 
 
Facial aging. Data for hair colour in the UK Biobank was collated from the UKB field-ID: 1757 
based on 498 740 participants where the question “Do people say that you look 
older/younger/about your age?” was asked. We re-coded the phenotype to compare individuals 
that self-report to look younger (coded as 1) against those that reported otherwise (coded as 0). 
The GWAS for the facial aging trait was performed as a quantitative phenotype through a linear 
mixed model implemented in BOLT-LMM 20, however the equivalent log(OR) estimates can be 
algebraically derived. 
 
Hair colour (Red Hair yes/no). Data for hair colour in the UK Biobank was collated from the UKB 
field-ID: 1747 based on 501,631 participants where the question “What best describes your 
natural hair colour? (If your hair colour is grey, the colour before you went grey)” was asked. 
Given previous findings on how the presence of natural red hair are associated with increased 
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risk of skin cancers, we re-coded the hair colour phenotype (coded as 1) to contrast red hair 
individuals against individuals of other hair colour (coded as 0). The GWAS for the red hair trait 
was performed as a quantitative phenotype through a linear mixed model implemented in 
BOLT-LMM 20, however the equivalent log(OR) estimates can be algebraically derived.  
 
Skin Colour. Data for skin colour in the UK Biobank was collated from the UKB field-ID: 1717 
based on 501,631 participants where the question “What best describes the colour of your skin 
without tanning?” was asked. We then converted the individuals’ response into an ordinal scale 
{1: very fair; 2: fair; 3: light olive; 4: dark olive; 5: brown; 6: black}, with phenotypes from 
individuals that did not or refused to response set to NA.  
 
Daily duration of walking and vigorous activity. Data for duration of vigorous activity in the UK 
Biobank was collated from the UKB field-ID: 914 where the question “How many minutes did 
you usually spend doing vigorous activities on a typical DAY?” was asked while data for 
duration of walks (UKB ID-field ) were available for 479 987 individuals that answered the 
question “How many minutes did you usually spend walking on a typical DAY?”. Responses on 
both questions were provided in units of minutes/day with an average value of  44.57 min/day 
(sd of 47.25) for duration of vigorous activity  and 60.96 min/day (sd of 77.03) for walking 
duration. The raw values for both duration of vigorous activity and walking were retained without 
transformation. These GWASs were performed as quantitative phenotypes through a linear 
mixed model implemented in BOLT-LMM 20.  
 
Selection of trait for the MVMR analysis 
Genetic instruments for each trait were derived from variants with genome-wide significant 
associations on their respective traits. Instruments from each individual candidate trait were 
then merged into a single set of SNP instruments (nSNPs=333), and we extracted the 
association estimates between these SNPs on each of the risk factors. Prior to any MVMR 
analysis, we first evaluated the strength of the combined instrument in predicting each risk 
factor via the conditional F-statistics implemented through the strength_mvmr() function in the 
MVMR R package by Sanderson et al. 19  (https://github.com/WSpiller/MVMR). Traits without a 
conditional F-statistics > 10 were dropped, resulting in less than 4 traits for the MVMR analysis. 
We then recompiled the combined instrument based on the remaining 3 traits (skin colour, 
episodes of childhood sunburn and vitamin D) and re-evaluated the strength of the newly 
compiled instruments (nSNPs = 209). The conditional F-statistics for the 3 traits were 13.15 for 
childhood sunburn, 11.44 for skin colour and 59.40 for 25(OH)D, fulfilling the criteria for strong 
instrument in the MVMR setting. The subsequent multivariable MR regression was performed 
via the mv_multiple function available in the TwoSampleMR package. We only present the 
MVMR finding from the 3-trait model as a main finding in the manuscript; however, the MVMR 
estimate from the original 8 candidate traits can be found in Supplementary Table 10 (caution: 







Supplementary Table 1. Comparison of the proportion of 25(OH)D variance 
explained by SNP instruments estimated using the UKB cohort 






Top 5 25(OH)D associated 
variants from Jiang et al.  SUNLIGHT 2.40%         3.08e-107 
6 
Top 6 25(OH)D variants from the 
UKBB including the rare 
CYP2R1 variant 
SUNLIGHT, 
Manousaki et al. 
(2017) 3.00% 1.30E-35 
78 All the above including novel loci 
UKBB 25(OH)D 
GWAS 3.90% 5.00E-08 
  





























Supplementary Table 2. Estimation of power for Mendelian randomization 
analyses for various cancers based on total sample size and proportion of 








Power to detect true OR per 
1 SD increase in 25(OH)D 
OR > 1.1 OR > 1.2 OR > 1.4 
Barret's Eso. and 
Esophageal cancer 27438 0.37 0.045 0.37 0.89 1.00 
Barret's Esophagus 23326 0.26 0.045 0.28 0.77 1.00 
Esophageal carcinoma 21271 0.19 0.045 0.22 0.65 1.00 
Breast cancer 228951 0.54 0.045 0.99 1.00 1.00 
ER+ breast cancer 175475 0.40 0.045 0.99 1.00 1.00 
ER- breast cancer 127442 0.17 0.045 0.80 1.00 1.00 
Endometrial cancer 121885 0.11 0.045 0.63 1.00 1.00 
EC Endometrial cancer 54884 0.16 0.045 0.43 0.94 1.00 
NEEC Endometrial cancer 36677 0.03 0.045 0.11 0.28 0.78 
Lung Cancer 27209 0.42 0.045 0.38 0.89 1.00 
Lung adenocarcinoma 18336 0.19 0.045 0.20 0.59 0.99 
Squamous cell lung cancer 18313 0.18 0.045 0.19 0.57 0.99 
Melanoma skin cancer 42399 0.38 0.045 0.53 0.98 1.00 
SCC (Keratinocyte 
cancers) 292755 0.03 0.045 0.50 0.97 1.00 
BCC (Keratinocyte 
cancers) 293989 0.05 0.045 0.70 1.00 1.00 
Neuroblastoma 4881 0.33 0.045 0.10 0.26 0.70 
Ovarian Cancer 66450 0.38 0.045 0.73 1.00 1.00 
ClearCell 42307 0.03 0.045 0.12 0.32 0.84 
Endometrioid 43751 0.06 0.045 0.18 0.55 0.99 
HighGrade serous 53978 0.24 0.045 0.54 0.98 1.00 
LowGrade serous 41953 0.02 0.045 0.09 0.23 0.68 
Mucinous 42358 0.03 0.045 0.12 0.32 0.84 
Pancreatic Cancer 3835 0.49 0.045 0.10 0.22 0.61 





Supplementary Table 3. MR association between 25(OH)D and skin cancers 
excluding 25(OH)D variants* associated with skin colour, facial aging and 
episodes of childhood sunburn 
 
Outcome Method SNPs Pvalue OR (95% CI) 
Melanoma MR Egger 54 0.58 1.06 (0.87 to 1.29) 
Melanoma Weighted median 54 0.18 1.14 (0.94 to 1.39) 
Melanoma Inverse variance weighted 54 0.59 1.04 (0.89 to 1.22) 
Melanoma Simple mode 54 0.61 1.16 (0.66 to 2.04) 
Melanoma Weighted mode 54 0.45 1.06 (0.91 to 1.24) 
     
BCC MR Egger 60 0.45 1.06 (0.91 to 1.23) 
BCC Weighted median 60 0.08 1.12 (0.98 to 1.27) 
BCC Inverse variance weighted 60 0.03 1.14 (1.01 to 1.29) 
BCC Simple mode 60 0.10 1.40 (0.95 to 2.06) 
BCC Weighted mode 60 0.06 1.11 (1.00 to 1.24) 
     
SCC MR Egger 60 0.21 0.88 (0.73 to 1.07) 
SCC Weighted median 60 0.90 1.01 (0.84 to 1.22) 
SCC Inverse variance weighted 60 0.93 0.99 (0.85 to 1.16) 
SCC Simple mode 60 0.42 1.25 (0.73 to 2.16) 
SCC Weighted mode 60 0.65 0.96 (0.82 to 1.13) 
 
*the SNP rs2270318 located in the HAL gene region were also removed. SNPs excluded due to pleiotropic association with sun 
expsoure, time spent outdoors or pigmentation related traits include: rs10887718,rs10985827,rs11127048,rs11542462,rs11846838, 
rs12123821,rs17765311,rs1972994,rs2270318,rs2975734,rs3750296,rs3768013,rs4390955,rs61816761,rs61891388,rs75360998, 
rs7559329,rs77924615,rs7801804,rs804281,rs9536961. P-values are two-sided, derived from z-scores of the association estimate, 












Supplementary Table 4. Reverse MR findings for changes in 25(OH)D 
concentration per genetically predicted doubling of odds on cancer risk. 
























BEEA 10 0.74 -0.001 -0.010 0.007 N 0.74 -0.001 -0.010 0.007 
Breast cancer 201 0.39 -0.002 -0.008 0.003 Y 0.68 -0.001 -0.006 0.004 
Endometrial  
cancer 18 0.99 0.000 -0.009 0.009 N 0.99 0.000 -0.009 0.009 
Melanoma skin 
cancer^ 18 0.51 -0.003 -0.013 0.006 Y 0.26 -0.003 -0.008 0.002 
SCC 14 0.43 0.004 -0.006 0.013 Y 0.18 -0.005 -0.013 0.002 
BCC 46 0.67 0.002 -0.006 0.010 Y 0.13 -0.004 -0.010 0.001 
Ovarian Cancer 26 0.41 -0.005 -0.017 0.007 Y 0.41 -0.004 -0.013 0.005 
Prostate Cancer 84 0.13 -0.003 -0.007 0.001 Y 0.21 -0.003 -0.007 0.001 
 
MR-PRESSO P-values are two-sided, derived from z-scores of the association estimate, and unadjusted for multiple comparison 
unless otherwise stated. 
 
Supplementary Table 5. MR association between per SD increase in 25(OH)D and 
cancer risk using sex-specific 25(OH)D genetic instruments. 
Cancer risk Instrument set SNPs used Pvalue OR (95% CI) 
Breast 
25(OH)D instruments in female only 
GWAS 33 0.50 1.02 (0.96 to 1.10) 
Endometrial 
25(OH)D instruments in female only 
GWAS 33 0.48 0.95 (0.83 to 1.09) 
Ovarian 
25(OH)D instruments in female only 
GWAS 33 0.11 0.92 (0.84 to 1.02) 
Prostate 
25(OH)D instruments in male only 
GWAS 34 0.16 1.07 (0.97 to 1.17) 







Supplementary Table 6. Comparison of MR association between one SD increase 
in 25(OH)D concentration and risk of cancer(s) with/without adjustment for 
vitamin D supplementation use. 
 
Cancer outcome Group 
NOT Adjusted for 
supplementation use 
 
Using original UKB 25(OH)D 
estimate from main analysis 
Adjusted for supplementation use 
 
 
Using Revez et al. UKB 25(OH)D estimate 
(SNPs clumped with r2=0.001) 




76 0.97 1.00 (0.84 to 1.18) 81 0.92 1.01 (0.84 to 1.22) 
Esophageal 
carcinoma 76 0.76 0.97 (0.78 to 1.20) 81 0.59 0.94 (0.75 to 1.18) 
BE and EA 
combined 76 0.82 0.98 (0.85 to 1.14) 81 0.88 0.99 (0.84 to 1.16) 
All breast cancer 
Breast 
74 0.60 1.02 (0.94 to 1.10) 74 0.91 1.00 (0.93 to 1.08) 
ER- breast cancer 74 0.94 1.00 (0.90 to 1.12) 74 0.95 1.00 (0.89 to 1.11) 




75 0.32 0.93 (0.80 to 1.07) 77 0.41 0.94 (0.81 to 1.09) 
EEC Endometrial 
cancer 75 0.32 0.92 (0.79 to 1.08) 77 0.27 0.91 (0.78 to 1.07) 
NEEC 
Endometrial 
cancer 74 0.94 1.01 (0.73 to 1.41) 77 0.94 0.99 (0.71 to 1.38) 
All EOC 
Ovarian 
76 0.03 0.90 (0.82 to 0.99) 79 0.09 0.91 (0.82 to 1.01) 
ClearCell EOC 76 0.36 0.86 (0.64 to 1.18) 79 0.33 0.85 (0.62 to 1.17) 
endometrioid EOC 76 0.56 0.94 (0.76 to 1.16) 79 0.56 0.93 (0.73 to 1.19) 
High grade serous 
EOC 76 0.15 0.92 (0.82 to 1.03) 79 0.33 0.94 (0.82 to 1.07) 
Low grade serous 
EOC 76 0.99 1.00 (0.71 to 1.40) 79 0.72 0.94 (0.66 to 1.34) 
mucinous EOC 76 0.58 0.94 (0.74 to 1.18) 79 0.99 1.00 (0.80 to 1.26) 
Prostate cancer Prostate 75 0.46 1.07 (0.89 to 1.29) 73 0.16 1.07 (0.97 to 1.18) 
Melanoma 
Skin 
69 0.31 1.09 (0.92 to 1.28) 74 0.17 1.13 (0.95 to 1.34) 
BCC 77 0.01 1.18 (1.05 to 1.33) 81 5.97E-04 1.23 (1.09 to 1.38) 
SCC 77 0.77 1.02 (0.88 to 1.19) 81 0.37 1.07 (0.92 to 1.24) 
 
BE=Barret’s esophagus, EA=Esophageal adenocarcinoma, SCC=Squamous cell carcinoma, BCC=Basal cell carcinoma, EOC= 
Epithelial ovarian cancer, NEEC=Non-endometrioid endometrial cancer, EEC= Endometrioid endometrial cancer. P refers to the P-
value of the MR association. P-values are two-sided, derived from z-scores of the association estimate, and unadjusted for multiple 
comparison unless otherwise stated. Note that we omitted cancer traits extracted from the MR-Base platform (lung cancers, 
neuroblastoma) for this comparison, due to the low SNP coverage in those datasets for robust evaluations. The GWAS summary 






Supplementary Table 7. MR association between 25(OH)D and cancer risk under 
natural log(25(OH)D) and rank-transformed 25(OH)D scales. 
 
 Outcome IVW MR Estimates per unit 
log(25OHD) increase 
IVW MR Estimates per SD 
increase in 25(OH)D  
(approx ~20 nmol/L increase) 
Cancers OR P-value OR P-value 
Barrett's Eso. and 
Esophageal cancer 
0.95 (0.68 to 1.32) 0.75 0.98 (0.85 to 1.14) 0.82 
Barrett's Esophagus 0.98 (0.66 to 1.46) 0.93 1.00 (0.84 to 1.18) 0.97 
Esophageal 
adenocarcinoma 
0.9 (0.56 to 1.46) 0.68 0.97 (0.78 to 1.20) 0.76 
          
Breast cancer 1.05 (0.88 to 1.25) 0.60 1.02 (0.94 to 1.1) 0.60 
ER+ breast cancer 1.07 (0.88 to 1.32) 0.49 1.03 (0.94 to 1.13) 0.51 
ER- breast cancer 1.02 (0.79 to 1.3) 0.90 1.00 (0.9 to 1.12) 0.94 
          
Endometrial cancer 0.85 (0.6 to 1.2) 0.34 0.93 (0.80 to 1.07) 0.32 
EC Endometrial cancer 0.83 (0.57 to 1.21) 0.33 0.92 (0.79 to 1.08) 0.32 
NEEC Endometrial 
cancer 
1.06 (0.49 to 2.28) 0.89 1.01 (0.73 to 1.41) 0.94 
          
Lung Cancer 1.19 (0.79 to 1.79) 0.42 0.95 (0.78 to 1.15) 0.59 
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Lung adenocarcinoma 1.13 (0.64 to 2.00) 0.67 0.88 (0.67 to 1.16) 0.37 
Squamous cell lung 
cancer 
1.01 (0.58 to 1.76) 0.97 0.98 (0.76 to 1.26) 0.86 
          
Types of skin cancers         
Melanoma 1.22 (0.85 to 1.77) 0.28 1.09 (0.92 to 1.28) 0.31 
Non-melanoma skin 
cancers 
1.11 (0.91 to 1.35) 0.38 - - 
SCC^ 1.08 (0.76 to 1.53) 0.66 1.02 (0.88 to 1.19) 0.77 
BCC^ 1.46 (1.12 to 1.9) 0.01 1.18 (1.05 to 1.33) 0.01 
          
Neuroblastoma 0.02 (0.05 to 0.79) 0.02 0.58 (0.34 to 1.01) 0.06 
          
Epithelial ovarian cancer 0.78 (0.63 to 0.96) 0.02 0.9 (0.82 to 0.99) 0.03 
ClearCell 0.67 (0.34 to 1.34) 0.26 0.86 (0.64 to 1.18) 0.36 
Endometrioid 0.87 (0.54 to 1.41) 0.57 0.94 (0.76 to 1.16) 0.56 
HighGrade serous 0.82 (0.63 to 1.07) 0.14 0.92 (0.82 to 1.03) 0.15 
LowGrade serous 0.95 (0.44 to 2.08) 0.90 1.00 (0.71 to 1.4) 0.99 
Mucinous 0.86 (0.5 to 1.5) 0.60 0.94 (0.74 to 1.18) 0.58 
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Pancreatic cancer 1.27 (0.27 to 6.05) 0.76 1.00 (0.54 to 1.85) 0.99 
          
Prostate cancer 1.15 (0.75 to 1.76) 0.53 1.07 (0.89 to 1.29) 0.46 
 
P-values are two-sided, derived from z-scores of the association estimate, and unadjusted for multiple comparison 




























Supplementary Table 8. Comparison of log(25(OH)D) effect estimates for 25(OH)D 





From original SUNLIGHT 
log(25(OH)D) GWAS 
log(25(OH)D) estimates 
in Yarmolinsky et al. 
log(25(OH)D) estimates from our 
UKBB GWAS 
EA NEA BETA P EA NEA BETA P EA NEA BETA P 
rs37559
67* 
GC T C -0.089 4.74E-
343 
T C 0.089 - T C -0.083 1.8E-1246 
rs12785
878 
DHCR7 T G 0.036 3.80E-
62 





A G 0.031 2.05E-
46 





T C 0.026 8.14E-
23 
T C 0.026 - T C 0.016 4.50E-35 
rs10745
742 
AMDH1 T C 0.017 1.88E-
14 





C G -0.017 4.72E-
09 
C G 0.019 - C G -0.014 8.70E-28 
 
*Note: The direction of effect for rs3755967 and rs8018720 used in the 25(OH)D MR analyses in Yarmolinsky et al. is 
seemingly different from those reported in the original Jiang et al SUNLIGHT GWAS and those obtained from our 
UKBB GWAS findings. P-values are two-sided, derived from z-scores of the 25OHD-GWAS association estimate, 
















Supplementary Table 9. Evaluation of instrument strength for the multivariable 
MR analysis adjusting for pigmentation related variables via the Sanderson-
Windmeijer conditional F-statistic. 
 
 
Traits used in the 
MVMR analysis Category 
Estimated Sanderson-Windmeijer conditional F-
statistic for each instrument 
Original MVMR model 
using all 8 traits 
(n=333) 
Reduced model with 25(OH)D, 
one chronic sun exposure 
trait and one pigmentation 
trait (n=209) 
number of episodes 
for childhood sunburn 
chronic sun 
exposure 7.78 13.15 
Daily duration of 
walking 
time spent 
outdoors 1.43 - 
Facial aging 
chronic sun 
exposure 7.21 - 
Red hair (yes/no) pigmentation 7.71 - 
Skin colour pigmentation 8.65 11.44 
Sleep duration 
time spent 
outdoors 4.79 - 
Daily duration of 
vigorous activity 
time spent 
outdoors 1.12 - 
25(OH)D 
Main exposure of 
interest 40.86 59.40 
 
The conditional F-statistics for each trait applied in the MVMR are estimated using the multivariable MR (MVMR) R 
package. Only results based on the reduced model (vitamin D, skin colour and number of episodes for childhood 
sunburn) were subsequently reported in the revised manuscript. The MVMR findings based on the original 8 trait 















Supplementary Table 10. Multivariable MR association between 25(OH)D and skin 
cancers adjusted for pigmentation related variables using the original 8 candidate 
traits 







OR (95% CI) per unit 
change in risk factor 
Episodes of 
childhood sunburn 
Melanoma 0.89 0.31 3.46E-
03 
2.45 (1.34 to 4.46) 
Daily walking 
duration (mins) 
Melanoma 0.01 0.01 0.48 1.01 (0.99 to 1.02) 
Facial aging Melanoma -2.08 0.53 9.82E-
05 
0.13 (0.04 to 0.36) 
Red hair (yes/no) Melanoma 3.87 1.36 4.44E-
03 
47.85 (3.33 to >99) 
Skin colour Melanoma 0.30 0.27 0.27 1.35 (0.80 to 2.28) 
Sleep duration 
(hours) 
Melanoma 0.43 0.37 0.24 1.54 (0.75 to 3.18) 
Daily duration of 
vigorous activities 
(mins) 




Melanoma 0.14 0.11 0.21 1.15 (0.92 to 1.43) 
      
Episodes of 
childhood sunburn 
BCC 1.83 0.21 3.08E-
18 
6.23 (4.13 to 9.40) 
Daily walking 
duration (mins) 
BCC 0.01 0.01 0.04 1.01 (1.00 to 1.02) 
Facial aging BCC 0.97 0.34 0.01 2.63 (1.34 to 5.17) 
Red hair (yes/no) BCC -0.14 0.73 0.85 0.87 (0.21 to 3.65) 
Skin colour BCC -0.52 0.18 4.69E-
03 
0.59 (0.41 to 0.85) 
Sleep duration 
(hours) 
BCC -0.11 0.24 0.65 0.89 (0.56 to 1.44) 
Daily duration of 
vigorous activities 
(mins) 




BCC 0.14 0.08 0.08 1.15 (0.99 to 1.34) 
      
Episodes of 
childhood sunburn 
SCC 2.61 0.26 3.84E-
23 
13.61 (8.12 to 22.81) 
Daily walking 
duration (mins) 
SCC 0.02 0.01 0.04 1.02 (1.00 to 1.03) 
Facial aging SCC 0.89 0.43 0.04 2.44 (1.04 to 5.71) 
Red hair (yes/no) SCC -0.16 0.92 0.86 0.86 (0.14 to 5.15) 
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Skin colour SCC -0.22 0.23 0.34 0.80 (0.51 to 1.26) 
Sleep duration 
(hours) 
SCC -0.08 0.31 0.78 0.92 (0.50 to 1.68) 
Daily duration of 
vigorous activities 
(mins) 




SCC 0.08 0.10 0.40 1.09 (0.89 to 1.32) 
 
BCC= Basal Cell Carcinoma; SCC= Squamous Cell Carcinoma. Marginal BETA reflects the marginal magnitude of 
association between the genetic effect of 25(OH)D SNPs exert on the risk factor of interest and skin cancer outcomes 
after conditioning on the genetic effect on remaining risk factors. Both the red hair and facial aging trait are binary 
phenotypes; hence the resultant marginal OR cannot be readily interpreted. Note that these estimates are highly 
vulnerable to weak instrument bias since some traits included in the model did not satisfy the strong instrument 
criteria (see Supplementary Table 8). All P-values are two-sided, derived from z-scores of the association estimate, 



























Note: MR Scatter plots and funnel plots are not shown for cancer traits obtained from the MR-
Base database. Those plots can be readily generated directly from the MR-Base platform. 
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Supplementary Figure 1. Scatter plot for the MR association between 25(OH)D 
and breast cancer risk. The upper panel represents the scatter plot for overall risk of 
breast cancer; lower panel represents findings for ER-negative and ER-positive breast 
cancers. The slope of each fitted line (highlighted in different colours) reflect the MR 
causal estimate derived from alternative 2SMR estimators. Each datapoint (n=74 SNPs) 
refers to the beta estimate of the exposure (vitaminD) and outcome(cancer risk) 




Supplementary Figure 2. Scatter plot for the MR association between 25(OH)D 
and endometrial cancer risk. The upper panel represents the scatter plot for overall 
risk of breast cancer; lower panel represents findings for Endometrioid (EEC) and Non-
Endometrioid (NEEC) endometrial cancer. The slope of each fitted line (highlighted in 
different colours) reflect the MR causal estimate derived from alternative 2SMR 
estimators. Each datapoint (n=75 SNPs) refers to the beta estimate of the exposure 
(vitaminD) and outcome(cancer risk) association, with the error bars reflecting the 






Supplementary Figure 3. Scatter plot for the MR association between 25(OH)D 
and EOC risk. Each panel represent the scatter plot for (A) overall risk of EOC; (B) 
clearcell EOC; (C) endometrioid EOC; (D) mucinous EOC; (E) high grade serous EOC 
and (F) low grade serous EOC. The slope of each fitted line (highlighted in different 
colours) reflect the MR causal estimate derived from alternative 2SMR estimators. Each 
datapoint (n=76 SNPs) refers to the beta estimate of the exposure (vitaminD) and 






































Supplementary Figure 4. Scatter plot for the MR association between 25(OH)D 
and prostate cancer risk. The slope of each fitted line (highlighted in different colours) 
reflect the MR causal estimate derived from alternative 2SMR estimators. Each 
datapoint (n=75 SNPs) refers to the beta estimate of the exposure (vitaminD) and 

















Supplementary Figure 5. Scatter plot for the MR association between 25(OH)D 
and the risk of BE and EA combined (BEEA). The upper panel represent the scatter 
plot for overall risk of BEEA; lower panel represent findings for risk of BE and EA 
separately. The slope of each fitted line (highlighted in different colours) reflect the MR 
causal estimate derived from alternative 2SMR estimators. Each datapoint (n=76 SNPs) 
refers to the beta estimate of the exposure (vitaminD) and outcome(cancer risk) 





Supplementary Figure 6. Scatter plot for the MR association between 25(OH)D 
and risk of skin cancers. The upper panel represents the scatter plot for overall risk of 
melanoma; lower panel represent findings for non-melanoma skin cancers, i.e. basal 
cell carcinoma (BCC) and squamous cell carcinoma (SCC). The slope of each fitted line 
(highlighted in different colours) reflect the MR causal estimate derived from alternative 
2SMR estimators. Each datapoint  (n=69 SNPs for melanoma; n=77 SNPs for BCC and 
SCC)  refers to the beta estimate of the exposure (vitaminD) and outcome(cancer risk) 







Supplementary Figure 7. Funnel plots for the MR associations between 25(OH)D 
and cancer risk. Funnel plots for individual subtype analyses were not shown. Most 
funnel plots show strong pattern of symmetry, the lack of datapoints on the left/right 
upper area of the distribution indicate minimal bias due to outlier effects. Panel (A) 
Breast cancer risk (B) Ovarian cancer risk (C) Endometrial cancer risk (D) Prostate 
cancer risk (E) Risk of Barret’s esophagus and Esophageal cancer combined (F) Risk of 

























Supplementary Figure 8. Sketch diagram illustrating potential inflation of MR OR 
due to ascertainment bias on history of skin disorder for the MR findings on 
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